All Stephan Schann (Chief Scientific Officer at Domain Therapeutics) articles
-
ArticleOutsmarting immune suppression through GPCR innovation
Immune resistance is one of cancer’s toughest tricks. By rethinking how we target GPCRs, scientists may finally have a way to modulate it with precision.


